Clinical Trials in China / NCT07100067
Recruiting
Not applicable
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
NCT07100067 · tracked via the Priya Life Science China tracker
Condition(s) studied
Relapsed/Refractory Multiple Myeloma(MM)
Investigational drug(s) / intervention(s)
LCAR- F33S cells intravenous infusion
LCAR- F33S cells intravenous infusion: Prior to infusion of the LCAR- F33S cell, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
Study summary
A prospective, single-arm, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-F33S in patients with relapsed/refractory multiple myeloma(Investigator-initiated Study).
Eligibility
Inclusion Criteria:
* Subjects voluntarily participate in clinical research.
* Age ≥18 years old.
* Eastern Cooperative Oncology Group (ECOG) score 0-2.
* Examination evidence of initial diagnosis of MM according to IMWG diagnostic criteria.
* Measurable lesions were present.
* Subjects have received treatment with one PI, one IMiD and a CD38 monoclonal antibody.
* Subjects have received at least three previous lines of multiple myeloma therapy, each with at least one complete therapy cycle, unless the best response to the therapeutic regimen was documented as disease progression (PD confirmed according to IMWG criteria).
* Expected survival ≥3 months.
* Clinical laboratory values in the screening period meet criteria.
Exclusion Criteria:
* Received previous therapy targeting FcRH5 targets.
* Prior antineoplastic therapy and meet exclusion criteria (before apheresis);
* Subjects had Plasma cell leukemia, Waldenstrom macroglobulinemia, POEMS syndrome, or primary AL amyloidosis at the time of screening.
* Subjects who were positive for any of HBsAg, HBV DNA, HCV-Ab, HCV RNA, and HIV-Ab;
* Life-threatening allergic reactions, hypersensitivity reactions, or intolerance to CAR-T cell formulations or their excipients, including DMSO, are known.
* Serious underlying diseases were present.
* Female subjects who were pregnant, breastfeeding, or planning to become pregnant while participating in this study or within 1 year of receiving study treatment.
* Also enrolled in other clinical studies.
Primary outcome measure(s)
- Dose-limiting toxicity (DLT) rate. — From LCAR-F33S cell infusion (Day 1) until the 30th day of follow-up period, assessed up to 30 days
DLT is classified according to the NCI-CTCAE V5.0 toxicity evaluation criteria and ASTCT consensus classification within 30 days after dose infusion (D1-D30), which is considered by the investigator or collaborator to be reasonably related to LCAR-F33S cell therapy. - Incidence, severity, and type of treatment-emergent adverse events (TEAEs) — From the date of signing ICF to the date 2 years after LCAR-F33S cell infusion
An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. - To determine the recommended dose for phase II clinical trials (RP2D) — through the last subject of DLT exploration completion, about 2years.
RP2D was established through accelerated titration design (ATD) and Bayesian Optimal Interval (BOIN) design. - Maximum concentration (Cmax) — From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion, assessed about 2 years
The maximum observed concentration of CAR positive T cells or transgene CAR copy number in peripheral blood. - Time to Cmax — From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion, assessed about 2 years
The time it takes to reach the maximum concentration of CAR positive T cells or transgene CAR copy number in peripheral blood. - Time to the last observed concentration — From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years
The time it takes to reach the last observed concentration of CAR positive T cells or transgene CAR copy number in peripheral blood. - Area Under the Curve (AUC) of the concentration — From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion, assessed about 2 years.
The exposure of CAR positive T cells or transgene CAR copy number in peripheral blood experienced by the subject in a certain time interval.
Trial sites (4)
| Facility | City | Region | Status |
|---|---|---|---|
| Beijing Boren Hospital | Beijing | China | Not Yet Recruiting |
| Institute of Hematology & Blood Diseases Hospital | Tianjin | China | Recruiting |
| Institute of Hematology & Blood Diseases Hospital | Tianjin | China | Recruiting |
| Wuhan Union Hospital | Wuhan | China | Recruiting |
More Nanjing Legend Biotech Co. trials in China
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07100067 on ClinicalTrials.gov ↗ ← All trials in China